Attached files

file filename
EX-23.1 - CONSENT OF EISNERAMPER LLP. - SOLIGENIX, INC.f10k2015ex23i_soligenix.htm
EX-10.31 - PURCHASE AGREEMENT DATED AS OF MARCH 22, 2016 BETWEEN THE COMPANY AND LINCOLN PARK CAPITAL FUND, LLC. - SOLIGENIX, INC.f10k2015ex10xxxi_soligenix.htm
EX-10.32 - REGISTRATION RIGHTS AGREEMENT DATED AS OF MARCH 22, 2016 BETWEEN THE COMPANY AND LINCOLN PARK CAPITAL FUND, LLC. - SOLIGENIX, INC.f10k2015ex10xxxii_soligenix.htm
EX-32.1 - CERTIFICATION - SOLIGENIX, INC.f10k2015ex32i_soligenix.htm
EX-32.2 - CERTIFICATION - SOLIGENIX, INC.f10k2015ex32ii_soligenix.htm
EX-31.2 - CERTIFICATION - SOLIGENIX, INC.f10k2015ex31ii_soligenix.htm
10-K - ANNUAL REPORT - SOLIGENIX, INC.f10k2015_soligenixinc.htm
EX-31.1 - CERTIFICATION - SOLIGENIX, INC.f10k2015ex31i_soligenix.htm

EXHIBIT 21.1

 

SUBSIDIARIES OF SOLIGENIX, INC.

 

The following represents a list of Soligenix, Inc.’s subsidiaries:

 

Name  Ownership   State of Incorporation
Enteron Pharmaceuticals, Inc.   100.00%  Delaware
Orasomal Technologies Inc.   75.30%  Delaware
DOR BioDefense Corp.   100.00%  Delaware
Soligenix BioPharma Canada Incorporated   100.00%  Canada
Soligenix UK Limited   100.00%  United Kingdom